IL6 and congenital rubella syndrome: Unlike chimeric antigen receptor T (CAR-T)–associated CRS, tebentafusp-related CRS was predictable in onset and resolution, did not include neurologic sequelae (i.e., no immune effector cell-associated neurotoxicity syndrome), and was usually managed with antipyretics and intravenous fluids, with supplemental oxygen or short courses of intravenous corticosteroids (majority received a single dose) when needed; anti–IL-6 (i.e., tocilizumab) was rarely used.